LOADING…
SPECIFICATIONS
01 / Metabolic / TZP-10
Dual GIP/GLP-1 receptor agonist. Lyophilized 10 mg vial. HPLC + MS COA per lot.
DOSE
QUANTITY
BUNDLE & SAVE
SHIPS
FRI · 2-5 BIZ DAYS
PAY WITH
USDC · SOLANA
REFERENCE
COMPOUND DATA AND PEER-REVIEWED CITATIONS FOR TIRZEPATIDE. FOR RESEARCH USE ONLY.
COMPOUND INFORMATION · TECHNICAL SPECIFICATIONS
MOLECULAR PROFILE
SYNONYMS
STORAGE REQUIREMENTS
LYOPHILIZED (POWDER)
-20°C · up to 2 years
RECONSTITUTED
2-8°C · up to 30 days
SOURCES & REFERENCES · PEER-REVIEWED RESEARCH · 8 CITATIONS FOR TIRZEPATIDE
JAMA
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
2024 · PMID 38078870
Aronne LJ, Sattar N et al.
VIEW SOURCE →
THE NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
2021 · PMID 34170647
Frías JP, Davies MJ et al.
VIEW SOURCE →
AMERICAN HEART JOURNAL
IMPORTANT RESEARCH NOTICE
NOT FOR HUMAN CONSUMPTION. THIS PRODUCT IS SOLD EXCLUSIVELY FOR RESEARCH AND EDUCATIONAL PURPOSES. IT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.
ALL CITATIONS ON THIS PAGE ARE SOURCED FROM PUBMED AND PUBCHEM PUBLIC DATABASES. THEY ARE PROVIDED FOR EDUCATIONAL REFERENCE ONLY AND SHOULD NOT BE INTERPRETED AS MEDICAL ADVICE OR PRODUCT CLAIMS.
BY PURCHASING THIS PRODUCT, YOU CONFIRM THAT YOU ARE A QUALIFIED RESEARCHER AND WILL USE IT IN ACCORDANCE WITH ALL APPLICABLE LAWS.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
2024 · PMID 37758044
Nicholls SJ, Bhatt DL et al.
VIEW SOURCE →